Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

Trial Details

NCT ID

NCT07405476

Phase

PHASE2

Sponsor

Emory University

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Zanidatamab
Resection
Patient Observation
Echocardiography Test
Multigated Acquisition Scan
Endoscopic Procedure

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Atlanta, Georgia, United States|33.749,-84.38798
Atlanta, Georgia, United States|33.749,-84.38798
Decatur, Georgia, United States|33.77483,-84.29631

Key Eligibility Criteria

Histologically or cytologically confirmed colon and/or rectal cancer planned for curative intent treatment at gastrointestinal clinics of Emory Uni…
Tumors must be HER2+ve (human epidermal growth factor receptor 2 \[HER2\] overexpression 3+ immunohistochemistry \[IHC\] or 2+ by IHC and positive …
Tumors must have RAS wildtype genotype
Radiologically measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →